Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print November 14, 2007
DOI: 10.2337/db07-1329

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-1329v1
57/2/470    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arbelaez, A. M.
Right arrow Articles by Cryer, P. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arbelaez, A. M.
Right arrow Articles by Cryer, P. E.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Attenuation of Counterregulatory Responses to Recurrent Hypoglycemia by Active Thalamic Inhibition: A Mechanism for Hypoglycemia-Associated Autonomic Failure

Ana Maria Arbelaez, M.D.1, William J. Powers, M.D.1, Tom O. Videen, Ph.D.1, Joseph L. Price, Ph.D.1, and Philip E. Cryer, M.D.1

1From the Departments of Pediatrics (A.M.A.), Neurology and Radiology (W.J.P. and T.O.V), Neurological Surgery (W.J.P.), Anatomy and Neurobiology (J.L.P.) and Medicine (P.E.C.), Washington University School of Medicine, St. Louis, Missouri and the Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina (W.J.P.)

Objective: Hypoglycemia, the limiting factor in the glycemic management of diabetes, is the result of the interplay of therapeutic insulin excess and compromised glycemic defenses. The key feature of the latter is an attenuated sympathoadrenal response to hypoglycemia that typically follows an episode of recent antecedent iatrogenic hypoglycemia, a phenomenon termed hypoglycemia-associated autonomic failure (HAAF) in diabetes. We investigated the role of cerebral mechanisms in HAAF by measuring regional brain activation during recurrent hypoglycemia with attenuated counterregulatory responses and comparing it to initial hypoglycemia in healthy individuals.

Research Design and Methods: We used [15O]water and positron emission tomography to measure regional cerebral blood flow (CBF) as a marker of brain synaptic activity during hyperinsulinemic hypoglycemic clamps (55 mg/dL [3.0 mmol/L]) in the naïve condition (Day 1) and after ~24 hours of interval interprandial hypoglycemia (Day 2) in nine healthy adults.

Results: Interval hypoglycemia produced attenuated sympathoadrenal, symptomatic and other counterregulatory responses to hypoglycemia on Day 2, a model of HAAF. Synaptic activity in the dorsal midline thalamus during hypoglycemia was significantly greater on Day 2 than Day 1 (P=0.004).

Conclusion: Greater synaptic activity associated with attenuated counterregulatory responses indicates that the dorsal midline thalamus plays an active inhibitory role in reducing sympathoadrenal and symptomatic responses to hypoglycemia when previous hypoglycemia has occurred, the key feature of HAAF in diabetes.


Correspondence: pcryer{at}wustl.edu

Key Words: Hypoglycemia • Diabetes • Hypoglycemia-Associated Autonomic Failure • Positron Emission Tomography • Thalamus


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.